Therefore, to investigate the genetic changes associated with the evolution of GATA-2 deficiency into MDS/AML, we performed whole-genome sequencing of MDS sample, which was compared with matched samples from nail, leukocyte at immunodeficiency, and bone marrow-derived mesenchymal stem cells (BM-MSCs). This evidence concerns the gene GATA2 and acute myeloid leukemia.